Could GLP-1 weight-loss drugs boost survival for colon cancer patients?
Colon cancer patients taking GLP-1 medications were less than half as likely to die within five years compared to those who weren’t on the drugs. – Image credit UC San Diego Today CANCER DIGEST – Nov. 15, 2025 – An analysis of data from nearly 7,000 colon cancer patients treated at cancer centers throughout California showed that patients who were taking a class of drug called glucagon-like peptide-1 (GLP-1) were more likely to survive compared to similar patients who were no
Niraparib nearly doubles progression-free survival in prostate cancer with specific genetic mutations
Men with prostate cancer whose tumors have specific genetic mutations saw a nearly 50 percent reduction in the risk of cancer progression when they received naraparib.
A new injectable cancer drug may offer hope to people with recurrent head and neck cancer
A simple injection of a new type of drug may offer new hope for patients whose head an neck cancers returns after chemotherapy and immunotherapy, results of an ongoing early phase clinical trial show.
A new blood test may detect HPV-linked throat cancer up to 10 years before diagnosis
A new blood test may detect throat cancer up to 10 years before diagnosis
Living near a Superfund pollution site may boost risk of aggressive types of breast cancer
Women diagnosed with breast cancer have a higher risk of aggressive and hard to treat cancers if they live near an EPA designated Superfund site.
Young adults with rectal bleeding linked to 8.5 times higher risk of colorectal cancer
Patients under age 50 who undergo colonoscopy to investigate rectal bleeding have been found to have eight times the risk of colorectal cancer
